Furthermore, the most frequently cancer-specific altered pathway of this Chinese CDC cohort was the p53/RB1 pathway, which was consistent with our finding of CDKN2A. In addition, CDKN2A-altered patients displayed a significantly worse OS than patients without alterations in both the KIRC and KIRP cohorts, as validated by Girgis et al. [41], who found that KIRC with biallelic inactivation of CDKN2A indicates a poor prognosis. This evidence concerns the gene CDKN2A and cancer.